Managing Partner of Biopharma Kostiantyn Yefymenko is considering the possibility of building a lysine plant in Bila Tserkva (Kyiv region), which is used as a feed additive in animal husbandry.
“I now have two options. To build a Biopharma plant in India and Brazil or a lysine plant. I bought a 10 ha plot with a supply of 100 cubic meters of water per hour, Biopharma consumes 75 cubic meters per day, the plant is the equivalent to processing 120,000 tonnes of grain. With the supply of water, the problem is solved, I’ve already bought 10 hectares, I have already connected electricity … I lean toward the lysine plant in Bila Tserkva,” he said on the sidelines of the Kyiv International Economic Forum.
He noted that he had already invested $2 million in the project.
As reported, the German pharmaceutical company STADA buys the pharmaceutical business of prescription and over-the-counter drugs of the Biopharma manufacturer of blood-derived products. The transaction is expected to close in December 2019.
Biopharma Managing Partner Kostiantyn Yefymenko together with partner Vasyl Khmelnytsky and financial investors will focus on developing the Biopharma blood plasma processing business, developing a new Biopharma plasma fractionation plant and a network of modern blood collection centers, as well as expanding its presence in international markets.
